The occurrence and development of tumors rely on the nutritional supply from blood vessels, which also serve as the main pathway for tumor metastasis. Inhibiting angiogenesis is one of the main strategies for cancer treatments. Chiral drugs, encouraged and inspired by chiral natural products, make up a major portion of marketed drugs. However, as an important source for synthetic chemistry and drug discovery, the counterpart of chiral natural products, the enantiomers, has received little attention. Here, we constructed a compound library containing 100 racemates (±)-1-100 and 4 pairs of enantiomers (33, 48, 59, 68) of 3,4-dioxygenated-4-aryl-quinolin-2(1H)-one alkaloids. Through extensive activity screening, we found that the compounds with 3R, 4R configuration, opposite to the natural products, exhibited potent angiogenesis inhibitory activity in zebrafish, while the 3S, 4S-configured natural derivatives have no effects. More importantly, compound (+)-48, named as (3R, 4R)-CHNQD-00728, significantly inhibited hepatic tumor growth in doxycin hydrochloride-induced liver-specific enlargement zebrafish. Examining the phenomenon and unlocking dark matter of enantiomeric natural products in innovative drugs discovery can provide a new perspective on organic synthesis and medicinal chemistry, thus enabling a broader exploration.

With the emergence of drug resistance and the consequential high morbidity and mortality rates, there is an urgent need to screen and identify new agents for the effective treatment of cancer. Terphenyls-a group of aromatic hydrocarbons consisting of a linear 1,4-diaryl-substituted benzene core-has exhibited a wide range of biological activities. In this study, we discovered a terphenyllin derivative-CHNQD-00824-derived from the marine compound library as a potential anticancer agent. The cytotoxic activities of the CHNQD-00824 compound were evaluated against 13 different cell lines with IC50 values from 0.16 to 7.64 μM. Further study showed that CHNQD-00824 inhibited the proliferation and migration of cancer cells, possibly by inducing DNA damage. Acridine orange staining demonstrated that CHNQD-00824 promoted apoptosis in zebrafish embryos. Notably, the anti-cancer effectiveness was verified in a doxycin hydrochloride (DOX)-induced liver-specific enlargement model in zebrafish. With Solafinib as a positive control, CHNQD-00824 markedly suppressed tumor growth at concentrations of 2.5 and 5 μM, further highlighting its potential as an effective anticancer agent.

This investigation was carried out to evaluate the bioavailability of a new capsule formulation of doxycycline (100 mg), doxycin, relative to the reference product, vibramycin (100 mg) capsules. The bioavailability was carried out in 24 healthy male volunteers who received a single dose (100 mg) of the test (A) and the reference (B) products after an overnight fast of at least 10 hours on 2 treatment days. The treatment periods were separated by a 2-week washout period. A randomized, balanced 2-way cross-over design was used. After dosing, serial blood samples were collected for a period of 48 hours. Plasma concentrations of doxycycline were analyzed by a sensitive and validated high-performance liquid chromatography assay. The pharmacokinetic parameters for doxycycline were determined using standard noncompartmental methods. The parameters AUC(0-t), AUC(0-infinity), Cmax, K(el), t(1/2) and Cmax/AUC(0-infinity) were analyzed statistically using log-transformed data. The time to maximum concentration (tmax) was analyzed using raw data. The parametric 90% confidence intervals of the mean values of the pharmacokinetic parameters: AUC(0-t), AUC(0-infinity), Cmax and Cmax/AUC(0-infinity) were within the range 80-125% which is acceptable for bioequivalence (using log-transformed data). The calculated 90% confidence intervals based on the ANOVA analysis of the mean test/reference ratios of AUC(0-t), AUC(0-infinity), Cmax and Cmax/AUC(0-infinity) were 95.98-109.56%, 92.21 to 107.66%, 93.90-112.56%, and 96.0 to 106.91% respectively. The test formulation was found bioequivalent to the reference formulation with regard to AUC(0-t), AUC(0-infinity), Cmax and Cmax/AUC(0-infinity) by the Schuirmann's two 1-sided t-tests. Therefore, the 2 formulations were considered to be bioequivalent.